Auriga Reiterates Buy Rating On Omnicell

According to Auriga, Omnicell OMCL Buy rating is reiterated. Auriga said that it is reiterating its BUY rating on Omnicell (OMCL) after a day of investor meetings last week. “The company occupies a solid #2 position (23% market share) behind market leader Carefusion (CFN, NR) and continues to be a net share gainer vs. CFN and distant #3 McKesson (MCK, BUY). We peg market growth at mid- to high-single digits and believe OMCL can exceed that via market share gains and new product upgrades. Longer term, OMCL is poised to benefit from stimulus requirements that expand focus to medication administration, beyond just electronic medical records (EMRs), anticipated in 2013. At this time we would continue to accumulate the stock on dips.” Omnicell closed yesterday at $15.41.